Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Ultimovacs. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Ultimovacs's earnings available for a low price, and how does
this compare to other companies in the same industry?
Ultimovacs is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Ultimovacs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Ultimovacs's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Øyvind Kongstun Arnesen, MD, serves as Chief Executive Officer at Ultimovacs AS since August 2012. Dr. Arnesen is experienced within the pharmaceutical industry including positions as Medical Director and Head of Clinical Operations Nordic at Boehringer Ingelheim (Norway) from 2007 until 2012, Medical Director at Bristol-Myers Squibb (Norway) from 2004 until 2007 and Clinical Trial Manager at AstraZeneca AS from 1995 until 1996. Dr. Arnesen holds a Medical Doctor (MD) from the University of Oslo, Norway.
Current Directorships and senior management positions:
• The Norwegian Pharmaceutical Product Compendium, Board Member
• Oslo Cancer Cluster, Board Member (Chairman)
• Vitmed AS, CEO and Board Member.
Previous Directorships and senior management positions in last five years:
• Nedre Bygdølund Sameie, Alternate Board Member
• The Norwegian Pharmaceutical Industry Association, Board member.
Øyvind's compensation has increased whilst company is loss making.
Øyvind's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Ultimovacs management team is about average.
Chief Executive Officer
Chief Financial Officer
Chief Operating Officer
Head of Research
Head of International Clinical Development
Jens Egil Bjørheim
Chief Medical Officer
Head of Clinical Operations
Chief Development Officer
Managing Director Ultimovacs AB
Director of Regulatory Affairs & QA
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Ultimovacs board of directors is about average.
Board of Directors
Kristin Louise Wilhelmsen
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was founded in 2011 and is headquartered in Oslo, Norway.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.